Inka Health, Subsidiary of Onco-Innovations Ltd., Welcomes AstraZeneca's Founding Role in AI-Oncology Consortium

Reuters

06-28

Inka Health, Subsidiary of Onco-Innovations Ltd., Welcomes AstraZeneca's Founding Role in AI-Oncology Consortium

Onco-Innovations Limited's subsidiary, Inka Health Corp., has received a formal Expression of Interest $(EOI)$ from AstraZeneca plc, indicating their intent to join the Predictive Oncology Outcomes using Multimodal AI (PROmAI) Consortium as a founding member. This consortium, spearheaded by Inka Health, aims to unite leading pharmaceutical companies and scientific experts to advance next-generation AI solutions in oncology. AstraZeneca's involvement is seen as a validation of the PROmAI initiative's potential impact in oncology research and development. The collaboration will initially focus on joint planning and strategic alignment, with possibilities for broader participation in future research and initiatives. Inka Health views this partnership as a strategic opportunity to lead in AI methodologies for oncology, emphasizing trust, transparency, and utility of AI-driven insights in drug development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onco-Innovations Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1043988) on June 27, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2546724057"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2546724057\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2546724057?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-28 06:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2546724057","market":"nz","top_or_hot":-1,"title":"Inka Health, Subsidiary of Onco-Innovations Ltd., Welcomes AstraZeneca's Founding Role in AI-Oncology Consortium","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Inka Health, Subsidiary of Onco-Innovations Ltd., Welcomes AstraZeneca's Founding Role in AI-Oncology Consortium\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Onco-Innovations Limited's subsidiary, Inka Health Corp., has received a formal Expression of Interest <a href=\"https://laohu8.com/S/EOI\">$(EOI)$</a> from AstraZeneca plc, indicating their intent to join the <a href=\"https://laohu8.com/S/POAI\">Predictive Oncology</a> Outcomes using Multimodal AI (PROmAI) Consortium as a founding member. This consortium, spearheaded by Inka Health, aims to unite leading pharmaceutical companies and scientific experts to advance next-generation AI solutions in oncology. AstraZeneca's involvement is seen as a validation of the PROmAI initiative's potential impact in oncology research and development. The collaboration will initially focus on joint planning and strategic alignment, with possibilities for broader participation in future research and initiatives. Inka Health views this partnership as a strategic opportunity to lead in AI methodologies for oncology, emphasizing trust, transparency, and utility of AI-driven insights in drug development.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onco-Innovations Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1043988) on June 27, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inka Health, Subsidiary of Onco-Innovations Ltd., Welcomes AstraZeneca's Founding Role in AI-Oncology Consortium</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInka Health, Subsidiary of Onco-Innovations Ltd., Welcomes AstraZeneca's Founding Role in AI-Oncology Consortium\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-28 06:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Inka Health, Subsidiary of Onco-Innovations Ltd., Welcomes AstraZeneca's Founding Role in AI-Oncology Consortium\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Onco-Innovations Limited's subsidiary, Inka Health Corp., has received a formal Expression of Interest <a href=\"https://laohu8.com/S/EOI\">$(EOI)$</a> from AstraZeneca plc, indicating their intent to join the <a href=\"https://laohu8.com/S/POAI\">Predictive Oncology</a> Outcomes using Multimodal AI (PROmAI) Consortium as a founding member. This consortium, spearheaded by Inka Health, aims to unite leading pharmaceutical companies and scientific experts to advance next-generation AI solutions in oncology. AstraZeneca's involvement is seen as a validation of the PROmAI initiative's potential impact in oncology research and development. The collaboration will initially focus on joint planning and strategic alignment, with possibilities for broader participation in future research and initiatives. Inka Health views this partnership as a strategic opportunity to lead in AI methodologies for oncology, emphasizing trust, transparency, and utility of AI-driven insights in drug development.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onco-Innovations Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1043988) on June 27, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1057294990.SGD","symbol_name":"Blackrock World Healthscience A2 SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250627:nNDLCnKMT:1","article_id":"2546724057","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2546724057","pubTimestamp":1751061617,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Onco-Innovations Limited's subsidiary, Inka Health Corp., has received a formal Expression of Interest  from AstraZeneca plc, indicating their intent to join the Predictive Oncology Outcomes using Multimodal AI  Consortium as a founding member. This consortium, spearheaded by Inka Health, aims to unite leading pharmaceutical companies and scientific experts to advance next-generation AI solutions in oncology. AstraZeneca's involvement is seen as a validation of the PROmAI initiative's potential impact in oncology research and development. The collaboration will initially focus on joint planning and strategic alignment, with possibilities for broader participation in future research and initiatives. Inka Health views this partnership as a strategic opportunity to lead in AI methodologies for oncology, emphasizing trust, transparency, and utility of AI-driven insights in drug development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intellige","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","SG9999001176.USD":"United Global Healthcare Acc USD","BK4082":"医疗保健设备","LU0557290698.USD":"施罗德环球可持续增长基金","LU1084165304.USD":"FIDELITY WORLD \"A\" (USD) ACC","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU0757432116.USD":"THREADNEEDLE (LUX) PAN EUROPEAN ESG EQUITIES \"AE\" (USD) ACC","LU0526926950.USD":"贝莱德欧洲基金","LU1003077747.HKD":"BGF GLOBAL EQUITY INCOME \"A6\" (HKDHDG) INC","LU0077335932.USD":"FIDELITY AMERICAN GROWTH \"A\" INC","LU0171293334.USD":"贝莱德英国基金A2","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU1119994496.HKD":"FIDELITY WORLD \"A\" (HKD) ACC","LU1078025761.USD":"NINETY ONE GSF EUROPEAN EQUITY \"A\" (USDHDG) ACC","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU0545039389.USD":"BGF GLOBAL EQUITY INCOME \"A2\" ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU1153584641.USD":"BGF EUROPEAN EQUITY INCOME \"A2\" (USDHDG) ACC","LU0499090636.EUR":"AZ FUND 1 DIVIDEND PREMIUM \"A-AZ\" ACC","LU1019632923.USD":"Blackrock European Equity Income A6 USD-H","LU0882574055.USD":"富达全球健康医疗A ACC","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","AZN.UK":"阿斯利康制药","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","03165":"华夏欧优股对冲","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","LU0969580561.USD":"贝莱德欧洲特别时机基金A2","LU0345777659.USD":"NINETY ONE GSF EUROPEAN EQUITY \"A\" (USD) INC","LU1019634622.SGD":"Blackrock European Equity Income A6 SGD-H","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","LU0047473722.SGD":"HSBC GIF EUROPE VALUE \"PD\" (SGD) INC","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","POAI":"Predictive Oncology","LU0997586432.USD":"FIDELITY SUSTAINABLE EUROPE EQUITY \"A\" (USDHDG) ACC","LU0496365809.HKD":"TEMPLETON GLOBAL INCOME \"A\" (HKD) INC (Q)","LU0640478417.SGD":"THREADNEEDLE (LUX) PAN EUROPEAN ESG EQUITIES \"AGH\" (SGDHDG) ACC","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD"},"translate_title":"Onco-Innovations Ltd.子公司Inka Health欢迎阿斯利康在AI-Oncology联盟中担任创始角色","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03165":0.6,"AZN.UK":0.9,"POAI":0.9},"content_text":"Inka Health, Subsidiary of Onco-Innovations Ltd., Welcomes AstraZeneca's Founding Role in AI-Oncology Consortium\n    \n\n        Onco-Innovations Limited's subsidiary, Inka Health Corp., has received a formal Expression of Interest $(EOI)$ from AstraZeneca plc, indicating their intent to join the Predictive Oncology Outcomes using Multimodal AI (PROmAI) Consortium as a founding member. This consortium, spearheaded by Inka Health, aims to unite leading pharmaceutical companies and scientific experts to advance next-generation AI solutions in oncology. AstraZeneca's involvement is seen as a validation of the PROmAI initiative's potential impact in oncology research and development. The collaboration will initially focus on joint planning and strategic alignment, with possibilities for broader participation in future research and initiatives. Inka Health views this partnership as a strategic opportunity to lead in AI methodologies for oncology, emphasizing trust, transparency, and utility of AI-driven insights in drug development.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onco-Innovations Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1043988) on June 27, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}